Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity Reactions in the Western Australian HIV Cohort Study
Top Cited Papers
Open Access
- 1 July 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (1) , 99-102
- https://doi.org/10.1086/504874
Abstract
Abacavir therapy is associated with significant drug hypersensitivity in ∼8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allelle. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701–negative recipients.Keywords
This publication has 10 references indexed in Scilit:
- Clinical and immunogenetic correlates of abacavir hypersensitivityAIDS, 2005
- Abacavir plus LamivudineDrugs, 2005
- Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavirAnnals of Pharmacotherapy, 2004
- Predisposition to abacavir hypersensitivity conferred byHLA-B*5701and a haplotypicHsp70-HomvariantProceedings of the National Academy of Sciences, 2004
- Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populationsPharmacogenomics, 2004
- Epidemiological risk factors for hypersensitivity reactions to abacavir*HIV Medicine, 2003
- Reasons for Early Abacavir Discontinuation in HIV-Infected PatientsAnnals of Pharmacotherapy, 2003
- Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirPublished by Elsevier ,2002
- Genetic variations in HLA-B region and hypersensitivity reactions to abacavirThe Lancet, 2002
- Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavirPublished by Elsevier ,2001